Search results
Results From The WOW.Com Content Network
Gemcitabine is in the nucleoside analog family of medication. [3] It works by blocking the creation of new DNA, which results in cell death. [3] Gemcitabine was patented in 1983 and was approved for medical use in 1995. [7] Generic versions were introduced in Europe in 2009 and in the US in 2010. [8] [9] It is on the WHO Model List of Essential ...
DNA exists in many possible conformations that include A-DNA, B-DNA, and Z-DNA forms, although only B-DNA and Z-DNA have been directly observed in functional organisms. [14] The conformation that DNA adopts depends on the hydration level, DNA sequence, the amount and direction of supercoiling, chemical modifications of the bases, the type and ...
GVD is a chemotherapy regimen, used for salvage treatment of relapsed or refractory Hodgkin disease, including those patients who relapse after stem cell transplantation. [1]
The downstream effect is promotion of cell death because cells would not be able to properly undergo DNA synthesis if they are lacking dTMP, a necessary precursor to dTTP. [2] Five agents were in clinical trials in 2002: raltitrexed, pemetrexed, nolatrexed, Plevitrexed( ZD9331/BGC9331), and GS7904L. [3] Examples include
Azacitidine is a chemical analogue of the nucleoside cytidine, which is present in DNA and RNA.It is thought to have antineoplastic activity via two mechanisms – at low doses, by inhibiting of DNA methyltransferase, causing hypomethylation of DNA, [16] and at high doses, by its direct cytotoxicity to abnormal hematopoietic cells in the bone marrow through its incorporation into DNA and RNA ...
This prevents DNA replication and transcription, causes DNA strand breaks, and leads to programmed cell death . These agents include etoposide , doxorubicin , mitoxantrone and teniposide . The second group, catalytic inhibitors, are drugs that block the activity of topoisomerase II, and therefore prevent DNA synthesis and translation because ...
ReGenesis is a Canadian science-fiction television series produced by The Movie Network and Movie Central in conjunction with Shaftesbury Films.The series, which ran for four seasons from 2004 to 2008, revolves around the scientists of NorBAC (North American Biotechnology Advisory Commission), a fictional organization with a lab based in the city of Toronto.
Gene knock-in originated as a slight modification of the original knockout technique developed by Martin Evans, Oliver Smithies, and Mario Capecchi.Traditionally, knock-in techniques have relied on homologous recombination to drive targeted gene replacement, although other methods using a transposon-mediated system to insert the target gene have been developed. [3]